MarketLens

What's Driving Telix's Latest FDA Resubmission for Pixclara®

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What's Driving Rocket Pharmaceuticals' Latest FDA Review for KRESLADI

5 months ago

What's Driving the Latest Market Volatility

5 months ago

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

4 months ago

What's Driving Basilea's Latest Surge

5 months ago

Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?

Telix Pharmaceuticals (TLX) has an average analyst price target implying 86.2% upside, though the metric's reliability is uncertain. Positive earnings estimate revisions could support the stock.

TLX

Stock News•3 weeks ago

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Telix's ProstACT SELECT Phase 1 study results for TLX591-Tx were published in Cancers journal, evaluating lesion concordance between PSMA-PET and SPECT imaging for patient selection.

TLX

Stock News•1 months ago

Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial

Replimune's stock surged over 135% since April after FDA leadership changes opened a path for RP1 BLA resubmission. A pivotal FDA AdCom is now crucial ahead of the August 2, 2026 approval decision.

REPL

Stock News•1 months ago

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

Lantheus received an FDA Complete Response Letter for LNTH-2501 (Ga 68 edotreotide), a PET imaging kit for SSTR+ neuroendocrine tumors, delaying its potential market entry.

LNTH